2023
Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis
Kingston P, Blauvelt A, Strober B, Armstrong A. Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis. Journal Of Psoriasis And Psoriatic Arthritis 2023, 8: 156-165. PMID: 38188537, PMCID: PMC10768812, DOI: 10.1177/24755303231201336.Peer-Reviewed Original ResearchSevere plaque psoriasisTreatment of psoriasisPlaque psoriasisMechanism of actionLong-term extension studyNovel oral medicationsOral PDE4 inhibitorPalms/solesAcceptable safety profileHigh-risk patientsTreatment of adultsWeeks of treatmentTreatment of ModeratePivotal clinical studiesType I interferonPASI 75Tuberculosis evaluationSevere psoriasisIL-23Oral medicationsIL-12Blood testsSafety profilePsoriasis pathogenesisTriglyceride levels
2019
Tofacitinib benefit‐risk profile in chronic plaque psoriasis
Strober B, Gottlieb A, Kerkhof P, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R. Tofacitinib benefit‐risk profile in chronic plaque psoriasis. British Journal Of Dermatology 2019, 180: e19-e19. DOI: 10.1111/bjd.17373.Peer-Reviewed Original ResearchBiologic treatmentSevere psoriasisPlaque psoriasisHigh doseChronic plaque psoriasisHerpes zoster infectionSevere plaque psoriasisAcceptable safety profileBenefit-risk profileNew oral drugsZoster infectionPatient yearsTofacitinib treatmentUlcerative colitisPatients' qualityRheumatoid arthritisSafety profileAppearance of skinClinical trialsOral drugsEffective treatmentSide effectsPsoriasisPatientsDrugs
2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungberg A, Acharya N, Reich K. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. Journal Of The American Academy Of Dermatology 2016, 76: 432-440.e17. PMID: 27889292, DOI: 10.1016/j.jaad.2016.09.026.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsIxekizumab-treated patientsSerious adverse eventsAdverse eventsIncidence rateClinical trialsMore treatment-emergent adverse eventsExposure-adjusted incidence ratesEtanercept-treated patientsIntegrated safety dataSafety of ixekizumabUnexpected safety findingsAcceptable safety profileLong-term safety outcomesSafety of biologicsAdditional long-term dataSafety findingsSafety profileCandida infectionsSafety dataSafety outcomesIxekizumabPatientsPsoriasisTrials